open access

Vol 14, No 6 (2019)
Review Papers
Published online: 2019-12-31
Get Citation

The antihypertensive drugs and contamination with carcinogenic nitrosamines

Jan Tatarkiewicz, Magdalena Izabela Bujalska-Zadrożny
DOI: 10.5603/FC.a2019.0093
·
Folia Cardiologica 2019;14(6):556-563.

open access

Vol 14, No 6 (2019)
Review Papers
Published online: 2019-12-31

Abstract

At the end of June 2018 small amounts of highly carcinogenic N–nitrosamine — N–nitrosodimethylamine (NDMA) contaminations were found in some of the angiotensin II receptor AT1 antagonists (sartans) used to treat arterial hypertension. By July 2019, four N–nitrosamine impurities had been identified in sartans: NDMA, N–nitrosodiethylamine, N‑nitrosodiisopropylamine and N-nitroso-N-methyl-4-aminobutyric acid. Seven manufacturers of three contaminated active substances (valsartan, losartan and irbesartan) from China, India and Mexico had also been identified. These compounds had infiltrated the active pharmaceutical ingredients probably as a consequence of ill-considered synthesis modifications. The number of people who have been prescribed contaminated valsartan alone is estimated at around 20 million worldwide. This paper discusses the role of sartans in medicine in the context of the physiological significance of the renin–angiotensin–aldosterone system as well as the role of tetrazole moiety in the mechanism of sartans receptor activity. The synthesis of tetrazole moiety and its modifications have been characterized as possible causes of the appearance of nitrosamine impurities in sartans. The toxicological properties of nitrosamines are also briefly outlined. The fact that nitrosamines had been entering medicines for at least five years without the knowledge of the authorities responsible for the safety of medicines has exposed a gross malfunctioning of the system intended to guarantee the safety of medicinal products. The valsartan scandal has forced changes to some drug regulations, in particular the requirements for analytical procedures.

Abstract

At the end of June 2018 small amounts of highly carcinogenic N–nitrosamine — N–nitrosodimethylamine (NDMA) contaminations were found in some of the angiotensin II receptor AT1 antagonists (sartans) used to treat arterial hypertension. By July 2019, four N–nitrosamine impurities had been identified in sartans: NDMA, N–nitrosodiethylamine, N‑nitrosodiisopropylamine and N-nitroso-N-methyl-4-aminobutyric acid. Seven manufacturers of three contaminated active substances (valsartan, losartan and irbesartan) from China, India and Mexico had also been identified. These compounds had infiltrated the active pharmaceutical ingredients probably as a consequence of ill-considered synthesis modifications. The number of people who have been prescribed contaminated valsartan alone is estimated at around 20 million worldwide. This paper discusses the role of sartans in medicine in the context of the physiological significance of the renin–angiotensin–aldosterone system as well as the role of tetrazole moiety in the mechanism of sartans receptor activity. The synthesis of tetrazole moiety and its modifications have been characterized as possible causes of the appearance of nitrosamine impurities in sartans. The toxicological properties of nitrosamines are also briefly outlined. The fact that nitrosamines had been entering medicines for at least five years without the knowledge of the authorities responsible for the safety of medicines has exposed a gross malfunctioning of the system intended to guarantee the safety of medicinal products. The valsartan scandal has forced changes to some drug regulations, in particular the requirements for analytical procedures.
Get Citation

Keywords

sartans, active pharmaceutical ingredient contamination, nitrosamines, tetrazoles chemistry

Supplementary Files (1)
plik dodatkowy
Download
91KB
About this article
Title

The antihypertensive drugs and contamination with carcinogenic nitrosamines

Journal

Folia Cardiologica

Issue

Vol 14, No 6 (2019)

Pages

556-563

Published online

2019-12-31

DOI

10.5603/FC.a2019.0093

Bibliographic record

Folia Cardiologica 2019;14(6):556-563.

Keywords

sartans
active pharmaceutical ingredient contamination
nitrosamines
tetrazoles chemistry

Authors

Jan Tatarkiewicz
Magdalena Izabela Bujalska-Zadrożny

References (32)
  1. Sörgel F, Kinzig M, Abdel-Tawab M, et al. The contamination of valsartan and other sartans, part 1: new findings. J Pharm Biomed Anal. 2019; 172: 395–405.
  2. Charoo NA, Ali AA, Buha SK, et al. Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities. AAPS PharmSciTech. 2019; 20(5): 166.
  3. Farrukh MJ, Tariq MH, Malik O, et al. Valsartan recall: global regulatory overview and future challenges. Ther Adv Drug Saf. 2019; 10: 2042098618823458.
  4. Moll D. Valsartan. Schweigen — im Einklang mit den Rechtsvorschriften. (Teil I, II i III). DAZ.online (Dtsch. Apoth. Ztg online), Stuttgart, 31.10.2018. https://www.deutsche-apotheker-zeitung.de/news/artikel/2018/10/30/schweigen-im-einklang-mit-den-rechtsvorschriften/chapter:1 oraz j.w./chapter:2 oraz j.w./chapter:3 (18.07.2019).
  5. Shanley A. Sartan recalls beg the question: is compendial impurity testing enough? Pharm Tech Eur. 2018; 30(10): 38.
  6. Bonner L. More trouble for valsartan with discovery of fourth carcinogen. https://www.pharmacist.com/article/more-trouble-valsartan-discovery-fourth-carcinogen (11.07.2019).
  7. FDA.ca.2018.07.17: Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products. Company announcement. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/prinston-pharmaceutical-inc-issues-voluntary-nationwide-recall-valsartan-and-valsartan-hctz-tablets (29.07.2019).
  8. EMA.ar.2019.02.14: Committee for Medicinal Products for Human Use (CHMP), dokument EMA/217823/2019, 14 February 2019. Assessment report, Referral under Article 31 of Directive 2001/83/EC angiotensin-II-receptor antagonists (sartans) containing a tetrazole group. https://www.ema.europa.eu/en/documents/referral/sartans-article-31-referral-chmp-assessment-report_en.pdf (18.07.2019).
  9. Chaszczewska-Markowska M, Sagan M, Bogunia-Kubik K. The renin–angiotensin–aldosterone system (RAAS) — physiology and molecular mechanisms of functioning. Post Hig Med Dosw. 2016; 70: 917–927.
  10. Gumułka SW. Neuroprzekaźniki peptydowe i lipidowe. In: Maśliński S, Ryżewski J. ed. Patofizjologia: podręcznik dla studentów medycyny, Tom 1. Wydawnictwo Lekarskie PZWL, Warszawa 2009: 215–242.
  11. Dézsi CA. The different therapeutic choices with ARBs. Which one to give? When? Why? Am J Cardiovasc Drugs. 2016; 16(4): 255–266.
  12. Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013; 65(2): 809–848.
  13. Takezako T, Unal H, Karnik SS, et al. Current topics in angiotensin II type 1 receptor research: focus on inverse agonism, receptor dimerization and biased agonism. Pharmacol Res. 2017; 123: 40–50.
  14. Mavromoustakos T, Agelis G, Durdagi S. AT1 antagonists: a patent review (2008–2012). Expert Opin Ther Pat. 2013; 23(11): 1483–1494.
  15. Pandarus V, Desplantier-Giscard D, Gingras G, et al. Greening the valsartan synthesis: Scale-up of Key Suzuki–Miyaura Coupling over SiliaCat DPP-Pd. Org Process Res Dev. 2013; 17(12): 1492–1497.
  16. Wang Gx, Sun Bp, Peng Ch. An improved synthesis of valsartan. Org Process Res Dev. 2011; 15(5): 986–988.
  17. Baumann M, Baxendale IR, Ley SV, et al. An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals. Beilstein J Org Chem. 2011; 7: 442–495.
  18. Buschmann H, Holzgrabe U. NDMA in valsartan. Eine Spurensuche. Dtsch Apoth Ztg [DAZ]. 2018; 158(29): 22–26.
  19. Lawson EC, Shook BC, Lanter JC. Tetrazole-based angiotensin II type 1 (AT1) antagonists for the treatment of heart failure and congestive hypertension. In: Dinges J, Lamberth C. ed. Bioactive heterocyclic compound classes: pharmaceuticals. First ed. Wiley-VCH Verlag GmbH & Co. KGaA 2012: 153–167.
  20. Pat.CN104045602A[en] (2014): Improved method for preparing tetrazole for valsartan. Inventors: 朱晓仁, 陕年平, 张文灵, 王鹏 (Zhu Xiaoren, Shan Nianping, Zhang Wenling, Wang Peng). Application filed by浙江华海药业股份有限公司(Zhejiang Huahai Pharmaceutical Co., Ltd.). https://patents.google.com/patent/CN104045602A/en (30.06.2019).
  21. Pat.WO2012001484A2 (2012): An improved process for the preparation of valsartan. Inventors: Chinta R.R., Nangi G.B.S., Nayini M.R. et al. Application filed by Aurobindo Pharma Limited. https://patents.google.com/patent/WO2012001484A2 (30.06.2019).
  22. Pat.CN104045602A[zh] (2014): 种缬沙坦成四氮唑的改进方法 (“Ulepszona metoda wytworzenia układu tetrazolowego walsartanu”). Wynalazcy: 朱晓仁, 陕年平, 张文灵, 王鹏 (Zhu Xiaoren, Shan Nianping, Zhang Wenling, Wang Peng). Wniosek patentowy złożony przez 浙江华海药业股份有限公司(Zhejiang Huahai Pharmaceutical Co., Ltd.), 11 s. https://patentimages.storage.googleapis.com/b3/9e/6a/36cc241161e4d3/CN104045602A.pdf (w jęz. chińskim z rycinami) oraz https://patents.google.com/patent/CN104045602A/zh (w jęz. chińskim bez rycin) (30.06.2019).
  23. IARC 1978: International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans: Some N-Nitroso Compounds. IARC Monogr Eval Carcinog Risk Chem Man 1978; 17: 1–349. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono17.pdf (8.07.2019).
  24. Hamon M. Les nitrates peuvent-ils induire une toxicité indirecte? Can nitrates lead to indirect toxicity? Ann Pharm Fr. 2007; 65(5): 347–355.
  25. Rostkowska K, Zwierz K, Różański A, et al. Formation and metabolism of N-Nitrosamines. Pol J Environ Stud. 1998; 7(6): 321.
  26. Buschmann H, Holzgrabe U. Noch mehr Nitrosamine. NDMA, NDEA, NDIPA — wie kommen die Verunreinigungen in die Sartane? Dtsch Apoth Ztg [DAZ]. 2019; 159(1–2): 50–54.
  27. Stahlmann R. Wie gefährlich ist NDMA in Valsartan? Eine bewertung aus Toxikologischer Sicht. Dtsch Apoth Ztg [DAZ. 2018; 158(30): 30.
  28. Hecht SS. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis. Proc Soc Exp Biol Med. 1997; 216(2): 181–191.
  29. Gushgari AJ, Halden RU. Critical review of major sources of human exposure to N-nitrosamines. Chemosphere. 2018; 210: 1124–1136.
  30. EDQM.ne.2019.06.13: EDQM: Control of nitrosamine impurities in sartans: revision of five Ph. Eur. Monographs. News. 13 June 2019, Strasbourg, France. https://www.edqm.eu/en/news/control-nitrosamine-impurities-sartans-revision-five-ph-eur-monographs (01.08.2019).
  31. EDQM.Eur.Ph.2019: EDQM: Pharmeuropa Useful information, July 2019. Comments concerning revised texts published in the 10th Edition (10.0). Strasbourg, France. https://www.edqm.eu/sites/default/files/medias/fichiers/PhEur/comments_concerning_revised_texts_published_in_the_10th_edition_10.0.pdf (01.08.2019).
  32. EDQM.up.CEP2019.06.18: EDQM: Update on the EDQM review of CEP applications for sartans and next steps (June 2019). 18 June 2019, Strasbourg, France. ttps://www.edqm.eu/en/news/update-edqm-review-cep-applications-sartans-and-next-steps-june-2019 (01.08.2019).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl